Modulation of the beta-adrenergic system during acute myocardial infarction: Rationale for a new clinical trial;Modulación del sistema betaadrenérgico durante el infarto agudo de miocardio: Justificación para un nuevo ensayo clínico

Revista Espanola de Cardiologia

Volumn 64, Issue SUPPL. 2, 2011, Pages 28-33

  Ibáñez, Borja ^a,b   Fuster, Valentín ^a,c   Macaya, Carlos ^b   Jiménez Borreguero, Jesús ^a,d   Iñiguez, Andrés ^e   Fernández Ortiz, Antonio ^b   Sanz, Ginés ^a   Sánchez Brunete, Vicente ^f  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^f Servicio de Urgencia Medica de Madrid SUMMA 112   (Spain)

Author keywords

Acute myocardial infarction; Beta blockers; Cardioprotection; Reperfusion injury

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG DOSAGE FORM COMPARISON; DRUG INDICATION; EARLY INTERVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; NEUROMODULATION; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 79961132142     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.02.028     Document Type: Article

References (33)

1. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-94.
2. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296-329.
3. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol. 2004;44:276-86. (Pubitemid 38950583)
4. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7. (Pubitemid 29290470)
5. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-62.
6. Sommers HM, Jennings RB. Ventricular fibrillation and myocardial necrosis after transient ischemia. Effect of treatment with oxygen, procainamide, reserpine, and propranolol. Arch Intern Med. 1972;129:780-9.
7. Roberts R, Croft C, Gold HK, Hartwell TD, Jaffe AS, Muller JE, et al. Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. N Engl J Med. 1984;311:218-25. (Pubitemid 14087663)
8. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823-7.
9. Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L, et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation. 1983;67:I32-41.
10. Risenfors M, Herlitz J, Berg CH, Dellborg M, Gustavsson G, Gottfridsson C, et al. Early treatment with thrombolysis and beta-blockade in suspected acute myocardial infarction: results from the TEAHAT Study. J Intern Med Suppl. 1991;734:35-42.
11. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993;22:407-16. (Pubitemid 23214552)
12. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422-37.
13. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol. 2004;43:1780-7. (Pubitemid 38622514)
14. Harjai KJ, Stone GW, Boura J, Grines L, Garcia E, Brodie B, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2003;91:655-60. (Pubitemid 36287453)
15. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation. 2000;102:166-72. (Pubitemid 30451772)
16. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-53.
17. Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115:2909-16. (Pubitemid 46915384)
18. Ibanez B, Cimmino G, Prat-González S, Vilahur G, Hutter R, García MJ, et al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. Int J Cardiol. 2011;147:428-32.
19. Ibanez B, Fuster V, Jiménez-Borreguero J, Badimon JJ. Lethal myocardial reperfusion injury: A necessary evil? Int J Cardiol. 2010. PMID: 21093938; Doi: 10.1016/j.ijcard.2010.10.056
20. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622-32.
21. St John Sutton M, Lee D, Rouleau JL, Goldman S, Plappert T, Braunwald E, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577-82. (Pubitemid 36628939)
22. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol. 2002;39:30-6. (Pubitemid 34059858)
23. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002. (Pubitemid 29529292)
24. Thiele H, Kappl MJ, Conradi S, Niebauer J, Hambrecht R, Schuler G. Reproducibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging. J Am Coll Cardiol. 2006;47:1641-5.
25. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374-9. (Pubitemid 36164969)
26. Mahrholdt H, Wagner A, Holly TA, Elliott MD, Bonow RO, Kim RJ, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation. 2002;106:2322-7. (Pubitemid 35244732)
27. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94:730-6. (Pubitemid 351744690)
28. Wu KC. Fighting the "fire" of myocardial reperfusion injury: how to define success? J Am Coll Cardiol. 2009;53:730-1.
29. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2007;26:452-9. (Pubitemid 350194566)
30. Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. J Am Coll Cardiol. 2009;2:569-76.
31. Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53:720-9.
32. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Lancet. 1988;1:921-3.
33. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985;6:199-226.